Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) – Analysts at Leerink Swann issued their Q3 2018 earnings per share estimates for Deciphera Pharmaceuticals in a research report issued to clients and investors on Monday, September 24th. Leerink Swann analyst A. Berens expects that the company will earn ($0.64) per share for the quarter. Leerink Swann currently has a “Underperform” rating and a $28.00 target price on the stock. Leerink Swann also issued estimates for Deciphera Pharmaceuticals’ Q4 2018 earnings at ($0.75) EPS, FY2018 earnings at ($2.70) EPS, FY2019 earnings at ($2.50) EPS, FY2020 earnings at ($3.27) EPS, FY2021 earnings at ($3.08) EPS and FY2022 earnings at ($2.39) EPS.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.03.

Other research analysts also recently issued reports about the stock. Canaccord Genuity assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Tuesday, August 7th. They issued a “buy” rating and a $55.00 price target on the stock. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a research report on Tuesday, July 24th. BidaskClub downgraded shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 13th. Cantor Fitzgerald began coverage on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 22nd. They issued an “overweight” rating and a $53.00 price objective on the stock. Finally, JMP Securities lifted their price objective on shares of Deciphera Pharmaceuticals to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, June 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the stock. Deciphera Pharmaceuticals presently has an average rating of “Buy” and an average target price of $48.09.

Deciphera Pharmaceuticals stock opened at $38.50 on Thursday. The company has a quick ratio of 18.44, a current ratio of 18.44 and a debt-to-equity ratio of 0.05. Deciphera Pharmaceuticals has a 1 year low of $15.15 and a 1 year high of $45.61.

Several institutional investors and hedge funds have recently made changes to their positions in DCPH. Redmile Group LLC increased its position in shares of Deciphera Pharmaceuticals by 79.9% in the second quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock worth $58,123,000 after acquiring an additional 655,800 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Deciphera Pharmaceuticals in the second quarter worth approximately $21,989,000. Orbimed Advisors LLC increased its position in shares of Deciphera Pharmaceuticals by 30.8% in the second quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock worth $78,924,000 after acquiring an additional 472,800 shares in the last quarter. Opaleye Management Inc. purchased a new position in shares of Deciphera Pharmaceuticals in the first quarter worth approximately $7,314,000. Finally, FMR LLC increased its position in shares of Deciphera Pharmaceuticals by 33.5% in the second quarter. FMR LLC now owns 1,182,091 shares of the company’s stock worth $46,515,000 after acquiring an additional 296,571 shares in the last quarter. 53.53% of the stock is currently owned by institutional investors.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Featured Story: What strategies should day traders use to execute a trade?

Earnings History and Estimates for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.